Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn's Disease

COVID-19 update:

In response to the COVID pandemic, Scripps Health has either temporarily suspended or limited enrollment with appropriate precautions for all clinical trials. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.

Trial ID:
IRB-16-6868
Gauree Konijeti
The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).

Inclusion Criteria: 1. Signed informed consent, by the participant or a legally acceptable representative. 2. Aged at least 18 years. 3. Initiating vedolizumab or another biologic agent for UC or CD. 4. Signed release form, by the participant or a legally acceptable representative, permitting abstraction of the participant's medical records at Baseline and during participation in the study. Exclusion Criteria: 1. The participant is enrolled in a clinical trial in which treatment for CD or UC is managed through a protocol. 2. Prior treatment with vedolizumab. 3. Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.

Why isn't this trial accepting new patients?

The trial may have a limited enrollment number, reached its maximum, or come to the end of its enrollment period. View trials that are recruiting

How else can Scripps help me?

We have a broad range of physician expertise and specialized medical services available. You can find a doctor online, call 1-800-SCRIPPS (1-800-727-4777) for personal help, or see related Scripps services.

How can I find trials that are accepting new participants?

For more information, see a list of trials that are recruiting, or call the clinical research office at 858-648-6402 for help.